Search research articles
Contact Us
Filters
Showing results (311-320 of 344) with videos related to
Page
of 35
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 2026
EP4 Antagonist ONO-4578 Plus Nivolumab and Chemotherapy in HER2-Negative Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer
Izuma Nakayama, Min-Hee Ryu, Sung Hee Lim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 21, 2024
First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial
Yelena Y Janjigian, Jaffer A Ajani, Markus Moehler, et al.
JCO Precision Oncology
|
August 1, 2025
Prognostic Indicators of Preoperative Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel Efficacy in Locally Advanced Gastroesophageal and Gastric Cancer: Integrating Biomarker Analysis and Clinicopathological Factors
Amane Jubashi, Izuma Nakayama, Naoya Sakamoto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 11, 2021
Circulating Tumor DNA Analysis Detects <i>FGFR2</i> Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer
Tomoko Jogo, Yoshiaki Nakamura, Kohei Shitara, et al.
BMC Cancer
|
February 23, 2023
INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG)
Lyn Ley Lam, Nick Pavlakis, Kohei Shitara, et al.
The New England Journal of Medicine
|
June 2, 2025
Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer
Kohei Shitara, Eric Van Cutsem, Mahmut Gümüş, et al.
Cancer Science
|
June 2, 2025
Landscape Analysis of CLDN18 Expression and Isoform Distribution in Solid Tumors: Insights From MONSTAR-SCREEN-2 Study
Tadayoshi Hashimoto, Naoko Iida, Yoshiaki Nakamura, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
August 20, 2024
Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial
Narikazu Boku, Takeshi Omori, Kohei Shitara, et al.
JAMA
|
April 18, 2023
Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial
Jun Watanabe, Kei Muro, Kohei Shitara, et al.
Nature Cancer
|
February 19, 2025
Atezolizumab following definitive chemoradiotherapy in patients with unresectable locally advanced esophageal squamous cell carcinoma - a multicenter phase 2 trial (EPOC1802)
Hideaki Bando, Shogo Kumagai, Daisuke Kotani, et al.
Page
of 35
Search research articles
Search
Showing results (311-320 of 344) with videos related to
Sort By:
Page
of 35
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 2026
EP4 Antagonist ONO-4578 Plus Nivolumab and Chemotherapy in HER2-Negative Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer
Izuma Nakayama, Min-Hee Ryu, Sung Hee Lim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 21, 2024
First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial
Yelena Y Janjigian, Jaffer A Ajani, Markus Moehler, et al.
JCO Precision Oncology
|
August 1, 2025
Prognostic Indicators of Preoperative Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel Efficacy in Locally Advanced Gastroesophageal and Gastric Cancer: Integrating Biomarker Analysis and Clinicopathological Factors
Amane Jubashi, Izuma Nakayama, Naoya Sakamoto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 11, 2021
Circulating Tumor DNA Analysis Detects <i>FGFR2</i> Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer
Tomoko Jogo, Yoshiaki Nakamura, Kohei Shitara, et al.
BMC Cancer
|
February 23, 2023
INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG)
Lyn Ley Lam, Nick Pavlakis, Kohei Shitara, et al.
The New England Journal of Medicine
|
June 2, 2025
Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer
Kohei Shitara, Eric Van Cutsem, Mahmut Gümüş, et al.
Cancer Science
|
June 2, 2025
Landscape Analysis of CLDN18 Expression and Isoform Distribution in Solid Tumors: Insights From MONSTAR-SCREEN-2 Study
Tadayoshi Hashimoto, Naoko Iida, Yoshiaki Nakamura, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
August 20, 2024
Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial
Narikazu Boku, Takeshi Omori, Kohei Shitara, et al.
JAMA
|
April 18, 2023
Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial
Jun Watanabe, Kei Muro, Kohei Shitara, et al.
Nature Cancer
|
February 19, 2025
Atezolizumab following definitive chemoradiotherapy in patients with unresectable locally advanced esophageal squamous cell carcinoma - a multicenter phase 2 trial (EPOC1802)
Hideaki Bando, Shogo Kumagai, Daisuke Kotani, et al.
Page
of 35